HINOVA PHARMACEUTICALS INC.

Highlights Hinova Pharmaceuticals Inc.

Equities

688302

CNE1000059F5

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-07-07 pm EDT			5-day change	1st Jan Change
24.77 ^CNY	-2.09%		+5.09%	-52.43%

Jul. 08	Hinova Pharmaceuticals Gets US FDA's Nod to Trial HP537 tablets	MT
Jul. 05	Hinova Pharmaceuticals Receives FDA Fast Track Designation for Hp518 for Treatment of Ar+ Triple-Negative Breast Cancer	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Hinova Pharmaceuticals Gets US FDA's Nod to Trial HP537 tablets	Jul. 08	MT
Hinova Pharmaceuticals Receives FDA Fast Track Designation for Hp518 for Treatment of Ar+ Triple-Negative Breast Cancer	Jul. 05	CI
Hinova Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 26	CI
China Stocks Fall Ahead of March Economic Data Release	Apr. 08	MT
Hinova Pharma Gets Nod to Trial HP501 Tablets; Shares Down 3%	Apr. 08	MT
China Healthcare Stocks Rally on Hopes for Government Support	Mar. 14	DJ
Hinova Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23	CI
Hinova Pharmaceuticals Gets Nod to Trial HP537 Tablets	Feb. 23	MT
Hinova Pharmaceuticals Gets Nod to Test Prostate Cancer Drug	Nov. 03	MT
Hinova Pharmaceuticals Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Hinova Pharmaceuticals to Resubmit Application for Deuterated Enzalutamide Soft Capsules	23-10-23	MT
Hinova Pharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Hinova Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Hinova Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Hinova Pharma Gets Regulatory Nod for Anti-Tumor Drug Trial	23-02-10	MT
Hinova Receives FDA Proceed Authorization for its IND Application for HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment	23-02-06	CI
Hinova Disclosed the Preclinical Results of HP518 (Oral AR PROTAC) at the 5th Annual TPD Summit	22-10-28	CI
Hinova Pharmaceuticals Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
Hinova Pharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-29	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Protect and grow your investments with the help of our experts

Secure my Investments

fermer